Literature DB >> 31949329

Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

Cláudia Viegas1, Augusto J de Matos1, Liliana R Leite-Martins1, Inês Viegas1, Rui R F Ferreira1, Hugo Gregório1, Andreia A Santos1.   

Abstract

The urokinase plasminogen activator system (uPAS) has been poorly investigated in veterinary oncology. The aim of this study was to determine uPA serum concentrations in healthy and oncologic cats to understand the potential value of uPA as a cancer biomarker. Serum samples were collected from 19 healthy cats and 18 cats with spontaneous malignant neoplasms and uPA was measured through a specific enzyme-linked immunosorbent assay kit. The differences between uPA values and their relation with intrinsic factors and clinicopathological parameters were analyzed using an analysis of variance (ANOVA) and independent t-test. The average serum concentration of uPA in cancerous cats (0.54 ± 0.22 ng/mL) differed from that of healthy cats (1.10 ± 1.16 ng/mL) but was not significantly influenced by cats' clinicopathological parameters or by the presence of metastases. This study describes, for the first time, the serum concentrations of uPA in cats and proposes directions for future studies to uncover the relevance of uPAS in feline carcinogenesis. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Year:  2020        PMID: 31949329      PMCID: PMC6923816     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  32 in total

Review 1.  Inflammation fuels tumor progress and metastasis.

Authors:  Jingyi Liu; Pengnian Charles Lin; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.

Authors:  T Maguire; D Chin; D Soutar; M J Duffy
Journal:  Int J Cancer       Date:  2000-02-15       Impact factor: 7.396

3.  Interference testing.

Authors:  Goce Dimeski
Journal:  Clin Biochem Rev       Date:  2008-08

4.  Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.

Authors:  Everardo Cobos; Cynthia Jumper; Charles Lox
Journal:  Clin Appl Thromb Hemost       Date:  2003-07       Impact factor: 2.389

Review 5.  The urokinase plasminogen activator system: a target for anti-cancer therapy.

Authors:  Salvatore Ulisse; Enke Baldini; Salvatore Sorrenti; Massimino D'Armiento
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

6.  Markers of the uPA system and common prognostic factors in breast cancer.

Authors:  Alessandro Marco Minisini; Dora Fabbro; Carla Di Loreto; Marta Pestrin; Stefania Russo; Giovanni Gerardo Cardellino; Claudia Andreetta; Giuseppe Damante; Fabio Puglisi
Journal:  Am J Clin Pathol       Date:  2007-07       Impact factor: 2.493

7.  Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.

Authors:  Wei Zhang; Dan Ling; Jie Tan; Jieqing Zhang; Li Li
Journal:  Oncol Rep       Date:  2012-11-20       Impact factor: 3.906

8.  Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Authors:  Susanne Fuessel; Kati Erdmann; Helge Taubert; Andrea Lohse-Fischer; Stefan Zastrow; Matthias Meinhardt; Karen Bluemke; Lorenz Hofbauer; Paolo Fornara; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Manfred P Wirth; Matthias Kotzsch
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

9.  Normality tests for statistical analysis: a guide for non-statisticians.

Authors:  Asghar Ghasemi; Saleh Zahediasl
Journal:  Int J Endocrinol Metab       Date:  2012-04-20

10.  Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Authors:  Omar Al-Janabi; Helge Taubert; Andrea Lohse-Fischer; Michael Fröhner; Sven Wach; Robert Stöhr; Bastian Keck; Max Burger; Wolf Wieland; Kati Erdmann; Manfred P Wirth; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Matthias Kotzsch; Susanne Füssel
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.